Tan, Yan Qin http://orcid.org/0000-0001-7769-2023
Sun, Bowen
Zhang, Xi
Zhang, Shuwei
Guo, Hui
Basappa, Basappa http://orcid.org/0000-0002-8844-468X
Zhu, Tao http://orcid.org/0000-0003-4130-1144
Sethi, Gautam http://orcid.org/0000-0002-8677-8475
Lobie, Peter E. http://orcid.org/0000-0002-8445-184X
Pandey, Vijay http://orcid.org/0000-0001-8704-0694
Article History
Received: 10 November 2023
Revised: 7 February 2024
Accepted: 8 February 2024
First Online: 26 February 2024
Competing interests
: The authors declare the following competing interests: B.B., P.E.L, and V.P. are listed as inventors on a patent application and derivatives thereof for NPB and NCK, which is used in this work (WO/2019/194520). P.E.L. is an equity holder in Sinotar Pharmaceuticals Ltd, which currently holds the license for this patent. All other authors have no competing interests to declare.
: All animal care and experimental protocols for in vivo studies was approved by the Laboratory Animal Ethics Committee (Certificate number: YW) at Peking University Shenzhen, and ethical approval was obtained from Tsinghua Shenzhen International Graduate School (Number: 9, Year 2020). No human research participants were involved in the present study.